Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 3, 2009, Pages 509-516

  Zang, Dae Young ^a   Yang, Dae Hyun ^a   Lee, Hae Wan ^a   Hwang, Se Won ^a   Song, Hun Ho ^a   Jung, Joo Young ^a   Kwon, Jung Hye ^a   Kim, Hyo Jung ^a   Kim, Jung Han ^a   Park, Sa Rah ^a   Kim, Min Jeong ^a   Jang, Kyung Mi ^a   Park, Choong Kee ^a   Kim, Jong Hyeok ^a   Lee, Bong Hwa ^a  

^a Hallym University   (South Korea)

Author keywords

Clinical trial; Docetaxel; S 1 (combination); Stomach neoplasm

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DOCETAXEL; ANTINEOPLASTIC AGENT; OXONIC ACID; S 1 (COMBINATION); TAXOID; TEGAFUR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SEPTIC SHOCK; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING; DRUG COMBINATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; STOMACH TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OXONIC ACID; RECURRENCE; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR;

EID: 58249130878     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0768-9     Document Type: Article

References (15)

1. S Cascinu F Graziano S Barni R Labianca G Comella R Casaretti L Frontini V Catalano AM Baldelli G Catalano 2001 A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer Br J Cancer 84 470 474 (Pubitemid 32215871)
2. R Greil O Psenak 2007 Hematopoietic growth factors: ESMO recommendations for the application Ann Oncol 18 Suppl 2 ii89 ii91
3. F Guéritte-Voegelein D Guénard F Lavelle MT Le Goff L Mangatal P Potier 1991 Relationships between the structure of taxol analogues and their antimitotic activity J Med Chem 34 992 998
4. F Kamangar GM Dores WF Anderson 2006 Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2137 2150 (Pubitemid 46655601)
5. W Koizumi M Kurihara S Nakano K Hasegawa 2000 Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 cooperative gastric cancer study group Oncology 58 191 197
6. M Mai Y Sakata R Kanamaru M Kurihara M Suminaga J Ota N Hirabayashi T Taguchi H Furue 1999 A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B) Gan To Kagaku Ryoho 26 487 496
7. D Mavroudis C Kourousis N Androulakis K Kalbakis S Agelaki S Kakolyris J Souglakos E Sarra N Vardakis D Hatzidaki G Sarmonis V Georgoulias 2000 Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial Am J Clin Oncol 23 341 344 (Pubitemid 32429142)
8. K Ridwelski T Gebauer J Fahlke H Kröning E Kettner F Meyer K Eichelmann H Lippert 2001 Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer Ann Oncol 12 47 51 (Pubitemid 32162447)
9. Y Sakata A Ohtsu N Horikoshi K Sugimachi Y Mitachi T Taguchi 1998 Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715 1720 (Pubitemid 28474225)
10. T Shirasaka K Nakano T Takechi H Satake J Uchida A Fujioka H Saito H Okabe K Oyama S Takeda N Unemi M Fukushima 1996 Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2, 4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats Cancer Res 56 2602 2606 (Pubitemid 26171684)
11. R Simon 1989 Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 10 (Pubitemid 19099520)
12. TJ Smith J Khatcheressian GH Lyman H Ozer JO Armitage L Balducci CL Bennett SB Cantor J Crawford SJ Cross G Demetri CE Desch PA Pizzo CA Schiffer L Schwartzberg MR Somerfield G Somlo JC Wade JL Wade RJ Winn AJ Wozniak AC Wolff 2006 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline J Clin Oncol 24 3187 3205 (Pubitemid 46638957)
13. A Sulkes J Smyth C Sessa LY Dirix JB Vermorken S Kaye J Wanders H Franklin N LeBail J Verweij 1994 Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC early clinical trials group Br J Cancer 70 380 383 (Pubitemid 2119649)
14. K Yamaguchi T Shimamura I Hyodo W Koizumi T Doi H Narahara Y Komatsu T Kato S Saitoh T Akiya M Munakata Y Miyata Y Maeda H Takiuchi S Nakano T Esaki F Kinjo Y Sakata 2006 Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer Br J Cancer 94 1803 1808 (Pubitemid 43884569)
15. K Yoshida M Ninomiya N Takakura N Hirabayashi W Takiyama Y Sato S Todo M Terashima M Gotoh J Sakamoto M Nishiyama 2006 Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer Clin Cancer Res 12 3402 3407 (Pubitemid 43917349)